Literature DB >> 20416377

Modafinil and methylphenidate for neuroenhancement in healthy individuals: A systematic review.

Dimitris Repantis1, Peter Schlattmann, Oona Laisney, Isabella Heuser.   

Abstract

The term neuroenhancement refers to improvement in the cognitive, emotional and motivational functions of healthy individuals through, inter alia, the use of drugs. Of known interventions, psychopharmacology provides readily available options, such as methylphenidate and modafinil. Both drugs are presumed to be in widespread use as cognitive enhancers for non-medical reasons. Based on a systematic review and meta-analysis we show that expectations regarding the effectiveness of these drugs exceed their actual effects, as has been demonstrated in single- or double-blind randomised controlled trials. Only studies with sufficient extractable data were included in the statistical analyses. For methylphenidate an improvement of memory was found, but no consistent evidence for other enhancing effects was uncovered. Modafinil on the other hand, was found to improve attention for well-rested individuals, while maintaining wakefulness, memory and executive functions to a significantly higher degree in sleep deprived individuals than did a placebo. However, repeated doses of modafinil were unable to prevent deterioration of cognitive performance over a longer period of sleep deprivation though maintaining wakefulness and possibly even inducing overconfidence in a person's own cognitive performance. Copyright 2010 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20416377     DOI: 10.1016/j.phrs.2010.04.002

Source DB:  PubMed          Journal:  Pharmacol Res        ISSN: 1043-6618            Impact factor:   7.658


  118 in total

1.  Cognitive-enhancing substance use at German universities: frequency, reasons and gender differences.

Authors:  Stefanie Mache; Patrick Eickenhorst; Karin Vitzthum; Burghard F Klapp; David A Groneberg
Journal:  Wien Med Wochenschr       Date:  2012-06-16

2.  Effect of modafinil on learning and task-related brain activity in methamphetamine-dependent and healthy individuals.

Authors:  Dara G Ghahremani; Golnaz Tabibnia; John Monterosso; Gerhard Hellemann; Russell A Poldrack; Edythe D London
Journal:  Neuropsychopharmacology       Date:  2011-02-02       Impact factor: 7.853

3.  Cosmetic neurology: the role of healthcare professionals.

Authors:  Kinan Muhammed
Journal:  Med Health Care Philos       Date:  2014-05

Review 4.  Is neuroenhancement by noninvasive brain stimulation a net zero-sum proposition?

Authors:  Anna-Katharine Brem; Peter J Fried; Jared C Horvath; Edwin M Robertson; Alvaro Pascual-Leone
Journal:  Neuroimage       Date:  2013-07-21       Impact factor: 6.556

Review 5.  Globalization and cognitive enhancement: emerging social and ethical challenges for ADHD clinicians.

Authors:  Ilina Singh; Angela M Filipe; Imre Bard; Meredith Bergey; Lauren Baker
Journal:  Curr Psychiatry Rep       Date:  2013-09       Impact factor: 5.285

6.  Distributive justice and cognitive enhancement in lower, normal intelligence.

Authors:  Mikael Dunlop; Julian Savulescu
Journal:  Monash Bioeth Rev       Date:  2014 Sep-Dec

7.  Methylphenidate: Brain Gain for the Epilepsy Drain.

Authors:  Jong Woo Lee
Journal:  Epilepsy Curr       Date:  2017 May-Jun       Impact factor: 7.500

Review 8.  [Methamphetamine : Epidemiology, clinical importance and sequelae of abuse].

Authors:  N Arnaud; R Thomasius
Journal:  Nervenarzt       Date:  2017-09       Impact factor: 1.214

9.  Statistical approaches to harmonize data on cognitive measures in systematic reviews are rarely reported.

Authors:  Lauren E Griffith; Edwin van den Heuvel; Isabel Fortier; Nazmul Sohel; Scott M Hofer; Hélène Payette; Christina Wolfson; Sylvie Belleville; Meghan Kenny; Dany Doiron; Parminder Raina
Journal:  J Clin Epidemiol       Date:  2014-12-08       Impact factor: 6.437

Review 10.  Prescription stimulant medication misuse: Where are we and where do we go from here?

Authors:  Lisa L Weyandt; Danielle R Oster; Marisa E Marraccini; Bergljot Gyda Gudmundsdottir; Bailey A Munro; Emma S Rathkey; Alison McCallum
Journal:  Exp Clin Psychopharmacol       Date:  2016-10       Impact factor: 3.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.